NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q2 2026 vs. Q1 2026
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 13 | 12 | −1 |
| Shares | 379.7K | 397.6K | +17.9K (+4.7%) |
| Value | $286.7K | $285.7K | −$905 (−0.3%) |
New holders (2)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 11,473 | $8.26K | 0.00% |
| HRT Financial LP | 10,515 | $7.00K | 0.00% |
Sold out (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Two Sigma Investments, LP | 44,445 | $33.6K |
| Meitav Dash Investments Ltd | 40,000 | $30.2K |
| Jane Street Group, LLC | 28,670 | $21.6K |